ClinicalTrials.gg
Active, not recruitingNCT07483645Updated Mar 19, 2026

Effectiveness and Acceptability of LISEFEX® (Liposomal Iron With Vitamin C and Fiber) in People With Iron Deficiency Anemia.

An observational study in Iron Deficiency Anemia, sponsored by Carnot Laboratories. Active, not recruiting at 1 site in Mexico. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-19.

Sponsored by Carnot Laboratories · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
74
Ages
18 Years and older
Sex
All
01

Study summary

Observational, descriptive, prospective, longitudinal, multicenter, non-interventionist and multicentric study in Mexican subjects diagnosed with mild to moderate iron deficiency anemia (ADH). Main objective:To evaluate the effectiveness and acceptability of LISEFEX® supplement in patients with mild to moderate iron deficiency anemia.Design The minimal risk study, no therapeutic interventions were carried out by the research team. The indication for supplementation with LISEFEX® was made by the treating physician as part of standard clinical practice, while the study was limited to systematic collection of clinical and laboratory information during participant follow-up.

Read the detailed description

The primary objective of this study was to describe the evolution of hemoglobin levels from baseline to weeks 1, 2, 4, 8 and 12 of supplementation with LISEFEX®.

Secondary objectives, the aim is to describe various hematological, biochemical and safety parameters throughout the follow-up period in both cohorts. In particular, the percentage of reticulocytes was evaluated basal and in weeks 2, 4, 8 and 12 of supplementation. Also, the values of mean corpuscular volume (MCV), mean corpuscular hemoglobin (HCM) and corpuscular hemoglobin concentration were described mean (CHCM) baseline and follow-up weeks 1, 2, 4, 8, and 12.

02

Conditions studied

  • Iron Deficiency Anemia

Keywords

  • Anemia
  • iron supplementation liposomal
  • hemoblogin
  • iron deficiency anemia
03

In context

Anemia, Iron-Deficiency

602 studies on the registry are indexed under Anemia, Iron-Deficiency; 93 are open to participants now.

This study's enrollment of 74 is below the median of 200 across 118 observational studies indexed under Anemia, Iron-Deficiency.

Browse Anemia, Iron-Deficiency studies →

Lead sponsor

Carnot Laboratories is the lead sponsor of 5 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Mexican population in the usual clínica

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of iron deficiency anemia.
  • Candidates over 18 years.
  • Candidates with signed.
  • Candidates who have been instructed by their treating physician to start treatment with LISEFEX
  • Candidates with the ability to swallow substances orally.

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or breastfeeding.
  • Having received any treatment in the last 3 months for iron deficiency anemia.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
74 participants (actual)
Patient registry
No

Groups and cohorts

  • Grupo 1

    two sachets of LISEFEX® daily

  • Gurpo 2

    two packets of LISEFEX® on alternate days.

06

What researchers measure

Primary outcomes

  1. Hemoglobin level

    Time frame: 12 weeks

07

Study locations

1 site
  • Winsett Rethman S.A. de C.V.
    Monterrey, Nuevo León 64040, Mexico
08

References and documents

Publications

  • Guideline on haemoglobin cutoffs to define anaemia in individuals and populations [Internet]. Geneva: World Health Organization; 2024. Available from http://www.ncbi.nlm.nih.gov/books/NBK602198/ PubMed 38530913 ↗
  • Waldvogel-Abramowski S, Waeber G, Gassner C, Buser A, Frey BM, Favrat B, Tissot JD. Physiology of iron metabolism. Transfus Med Hemother. 2014 Jun;41(3):213-21. doi: 10.1159/000362888. Epub 2014 May 12. PubMed 25053935 ↗
  • von Siebenthal HK, Gessler S, Vallelian F, Steinwendner J, Kuenzi UM, Moretti D, Zimmermann MB, Stoffel NU. Alternate day versus consecutive day oral iron supplementation in iron-depleted women: a randomized double-blind placebo-controlled study. EClinicalMedicine. 2023 Nov 3;65:102286. doi: 10.1016/j.eclinm.2023.102286. eCollection 2023 Nov. PubMed 38021373 ↗
  • Ucan A, Kaya ZI, Yilmaz EO, Vasi I, Ozgeyik MO. Comparing therapeutic effects of alternate day versus daily oral iron in women with iron deficiency anemia: A retrospective cohort study. Medicine (Baltimore). 2023 Jul 28;102(30):e34421. doi: 10.1097/MD.0000000000034421. PubMed 37505179 ↗
  • Stoffel NU, Zeder C, Brittenham GM, Moretti D, Zimmermann MB. Iron absorption from supplements is greater with alternate day than with consecutive day dosing in iron-deficient anemic women. Haematologica. 2020 May;105(5):1232-1239. doi: 10.3324/haematol.2019.220830. Epub 2019 Aug 14. PubMed 31413088 ↗
  • Pisani A, Riccio E, Sabbatini M, Andreucci M, Del Rio A, Visciano B. Effect of oral liposomal iron versus intravenous iron for treatment of iron deficiency anaemia in CKD patients: a randomized trial. Nephrol Dial Transplant. 2015 Apr;30(4):645-52. doi: 10.1093/ndt/gfu357. Epub 2014 Nov 13. PubMed 25395392 ↗
  • Obeagu EI, Obeagu GU, Ukibe NR, Oyebadejo SA. Anemia, iron, and HIV: decoding the interconnected pathways: A review. Medicine (Baltimore). 2024 Jan 12;103(2):e36937. doi: 10.1097/MD.0000000000036937. PubMed 38215133 ↗
  • Mejia-Rodriguez F, Mundo-Rosas V, Garcia-Guerra A, Mauricio-Lopez ER, Shamah-Levy T, Villalpando S, De la Cruz-Gongora V. Prevalencia de anemia en la poblacion mexicana: analisis de la Ensanut Continua 2022. Salud Publica Mex. 2023 Jun 14;65:s225-s230. doi: 10.21149/14771. Spanish. PubMed 38060969 ↗
  • Mastrogiannaki M, Matak P, Peyssonnaux C. The gut in iron homeostasis: role of HIF-2 under normal and pathological conditions. Blood. 2013 Aug 8;122(6):885-92. doi: 10.1182/blood-2012-11-427765. Epub 2013 May 15. PubMed 23678007 ↗
  • Malhotra J, Garg R, Malhotra N, Agrawal P. Oral Liposomal Iron: A Treatment Proposal for Anemia. World J Anemia 2017;1(4):1-6.
  • Li N, Zhao G, Wu W, Zhang M, Liu W, Chen Q, Wang X. The Efficacy and Safety of Vitamin C for Iron Supplementation in Adult Patients With Iron Deficiency Anemia: A Randomized Clinical Trial. JAMA Netw Open. 2020 Nov 2;3(11):e2023644. doi: 10.1001/jamanetworkopen.2020.23644. PubMed 33136134 ↗
  • Kaundal R, Bhatia P, Jain A, Jain A, Nampoothiri RV, Mishra K, Jandial A, Goni D, Sandal R, Jindal N, Meshram A, Sharma R, Khaire N, Singh C, Khadwal A, Prakash G, Das R, Varma N, Varma S, Malhotra P, Lad DP. Randomized controlled trial of twice-daily versus alternate-day oral iron therapy in the treatment of iron-deficiency anemia. Ann Hematol. 2020 Jan;99(1):57-63. doi: 10.1007/s00277-019-03871-z. Epub 2019 Dec 6. PubMed 31811360 ↗
  • Hussain U, Zia K, Iqbal R, Saeed M, Ashraf N. Efficacy of a Novel Food Supplement (Ferfer(R)) Containing Microencapsulated Iron in Liposomal Form in Female Iron Deficiency Anemia. Cureus. 2019 May 7;11(5):e4603. doi: 10.7759/cureus.4603. PubMed 31309026 ↗
  • Hess SY, McLain AC, Frongillo EA, Afshin A, Kassebaum NJ, Osendarp SJM, Atkin R, Rawat R, Brown KH. Challenges for Estimating the Global Prevalence of Micronutrient Deficiencies and Related Disease Burden: A Case Study of the Global Burden of Disease Study. Curr Dev Nutr. 2021 Nov 18;5(12):nzab141. doi: 10.1093/cdn/nzab141. eCollection 2021 Dec. PubMed 34993390 ↗
  • Gomez-Ramirez S, Brilli E, Tarantino G, Munoz M. Sucrosomial(R) Iron: A New Generation Iron for Improving Oral Supplementation. Pharmaceuticals (Basel). 2018 Oct 4;11(4):97. doi: 10.3390/ph11040097. PubMed 30287781 ↗
  • Goddard AF, James MW, McIntyre AS, Scott BB; British Society of Gastroenterology. Guidelines for the management of iron deficiency anaemia. Gut. 2011 Oct;60(10):1309-16. doi: 10.1136/gut.2010.228874. Epub 2011 May 11. PubMed 21561874 ↗
  • GBD 2021 Anaemia Collaborators. Prevalence, years lived with disability, and trends in anaemia burden by severity and cause, 1990-2021: findings from the Global Burden of Disease Study 2021. Lancet Haematol. 2023 Sep;10(9):e713-e734. doi: 10.1016/S2352-3026(23)00160-6. Epub 2023 Jul 31. PubMed 37536353 ↗
  • Eichner ER. Anemia in Athletes, News on Iron Therapy, and Community Care During Marathons. Curr Sports Med Rep. 2018 Jan;17(1):2-3. doi: 10.1249/JSR.0000000000000435. No abstract available. PubMed 29315098 ↗
  • Ding B, Yi X, Li L, Yang H. Assessment of ferrous glycinate liposome absorption using in situ single-pass perfusion model. Int J Food Eng 2017 Aug;13(9):0358.
  • Cook JD, Reddy MB. Effect of ascorbic acid intake on nonheme-iron absorption from a complete diet. Am J Clin Nutr. 2001 Jan;73(1):93-8. doi: 10.1093/ajcn/73.1.93. PubMed 11124756 ↗
  • Chaparro CM, Suchdev PS. Anemia epidemiology, pathophysiology, and etiology in low- and middle-income countries. Ann N Y Acad Sci. 2019 Aug;1450(1):15-31. doi: 10.1111/nyas.14092. Epub 2019 Apr 22. PubMed 31008520 ↗
  • Cengiz A, Kahyaoglu T, Schroen K, Berton-Carabin C. Oxidative stability of emulsions fortified with iron: the role of liposomal phospholipids. J Sci Food Agric. 2019 Apr;99(6):2957-2965. doi: 10.1002/jsfa.9509. Epub 2019 Jan 17. PubMed 30471119 ↗
  • Cappellini MD, Musallam KM, Taher AT. Iron deficiency anaemia revisited. J Intern Med. 2020 Feb;287(2):153-170. doi: 10.1111/joim.13004. Epub 2019 Nov 12. PubMed 31665543 ↗
  • Brugnara C. A hematologic "gold standard" for iron-deficient states? Clin Chem. 2002 Jul;48(7):981-2. No abstract available. PubMed 12089163 ↗
  • Bastida G, Herrera-de Guise C, Algaba A, Ber Nieto Y, Soares JM, Robles V, Bermejo F, Saez-Gonzalez E, Gomollon F, Nos P. Sucrosomial Iron Supplementation for the Treatment of Iron Deficiency Anemia in Inflammatory Bowel Disease Patients Refractory to Oral Iron Treatment. Nutrients. 2021 May 22;13(6):1770. doi: 10.3390/nu13061770. PubMed 34067320 ↗
  • Baomiao D, Xiangzhou Y, Li L, Hualin Y. Evaluation of iron transport from ferrous glycinate liposomes using Caco-2 cell model. Afr Health Sci. 2017 Sep;17(3):933-941. doi: 10.4314/ahs.v17i3.37. PubMed 29085422 ↗
  • Banerjee A, Athalye S, Shingade P, Khargekar V, Mahajan N, Madkaikar M, Khargekar N. Efficacy of daily versus intermittent oral iron supplementation for prevention of anaemia among pregnant women: a systematic review and meta-analysis. EClinicalMedicine. 2024 Jul 17;74:102742. doi: 10.1016/j.eclinm.2024.102742. eCollection 2024 Aug. PubMed 39114275 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2025 to primary completion in Feb 2026, 9 months.

Of 54 observational studies under Anemia, Iron-Deficiency, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 35. This study's 9 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2026
First posted
Mar 19, 2026
StartActual
May 6, 2025
Primary completionActual
Feb 15, 2026
CompletionEst.
Mar 30, 2026
Last update
Mar 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07483645
Lead sponsor
Carnot Laboratories
Responsible party
Sponsor
First posted
Mar 19, 2026
Start date
May 6, 2025
Primary completion
Feb 15, 2026
Completion
Mar 30, 2026 (estimated)
Last update
Mar 19, 2026

Study contacts

Iris E Torres Garcia, Medico
principal investigator
Leonardo R Aguilar, Medico
principal investigator
Willy Nava, Medico
principal investigator
Edgar U Coronado, Medico
principal investigator

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion